|

Identifying Biomarkers in Alzheimer's Disease

RECRUITINGSponsored by Chinese University of Hong Kong
Actively Recruiting
SponsorChinese University of Hong Kong
Started2018-09-01
Est. completion2030-12-31
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05655650

Summary

Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is the only cause of death among the top ten causes that has no prevention or cure . It is believed that novel treatment of AD needs to start early or even at the prodromal stage in order to be effective. Therefore, there is an urgent need to find accurate methods of early detection before patients with AD develop clinical dementia. This study aims to identify biomarkers for AD in local Chinese population. this study hypothesizes blood-based proteomics, retinal imaging, ASL-MRP and tau PET can improve the accuracy and staging of AD.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* Chinese ethnicity
* \[For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)

Exclusion Criteria:

* Clinical diagnosis of non-AD dementia
* contraindication for MRI or PET

Conditions3

Alzheimer DiseaseAlzheimer's DiseaseNeuro-Degenerative Disease

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.